Advertisements


Valeant Pharmaceuticals: Intrigued…Really?

Deutsche Bank analyst Gregg Gilbert is warming up the the controversial drug maker. Here's why.....»»

Category: blogSource: barronsMay 19th, 2017

Valeant Pharmaceuticals Intl (NYSE:VRX) Advances 6.37%

Valeant Pharmaceuticals Intl (NYSE:VRX) Advances 6.37% Overall, the bias in prices is: Upwards. Short term: Prices are moving. Intermediate term: Prices are trending. Note: this chart shows extraordinary price action t.....»»

Category: topSource: livetradingnews12 hr. 11 min. ago

Valeant (VRX) Touches 52-Week High: Is the Stock Officially Back?

Shares of Valeant Pharmaceuticals (VRX) surged more than 2% higher on Wednesda.....»»

Category: dealsSource: nyt22 hr. 56 min. ago

The Bill Ackman problem everyone forgot is now at threat-level substantial

Reuters The insider trading case against Pershing Square founder Bill Ackman and Valeant Pharmaceuticals may go to trial. Investors in Aller.....»»

Category: topSource: businessinsiderDec 8th, 2017

Vetr Upgrades Valeant After Price Dips

The Vetr crowd on Thursday upgraded its rating on Valeant Pharmaceuticals International, Inc. (NYSE: VRX), from 4 stars (Buy), issued two days ago, to 5 s.....»»

Category: blogSource: benzingaDec 7th, 2017

Valeant is again borrowing in the bond market to repay debt

Valeant Pharmaceuticals International Inc. said Monday it is once again borrowing in the bond market to repay debt. The Laval, Quebec-based company said it is planning to offer $1 billion of senior notes due 2025. Proceeds will used to rep.....»»

Category: topSource: marketwatchDec 4th, 2017

Next Stop For Valeant Pharmaceuticals Stock: $19

Next Stop For Valeant Pharmaceuticals Stock: $19.....»»

Category: topSource: seekingalphaDec 4th, 2017

Inside Valeant"s Bid to Be a Normal Drug Company

Valeant Pharmaceuticals, which has been Exhibit A of corporate turbulence since 2015, is trying to get back to being a normal drug company. But it faces a steep climb to good health......»»

Category: smallbizSource: wsjNov 28th, 2017

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Technicals in Focus

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Technicals in Focus Overall, the bias in prices is: Upwards. Short term: Prices are moving. Intermediate term: Prices are trending. Note: this chart shows extraordinary price action to the.....»»

Category: topSource: livetradingnewsNov 24th, 2017

Can Valeant (VRX) Turn Around on Rebuilding Initiatives?

Valeant (VRX) has performed much better so far in 2017 compared to last year on the back of rebuilding initiatives. Shares of Valeant Pharmaceuticals.....»»

Category: dealsSource: nytNov 21st, 2017

Includes J.C. Penney, Valeant Pharmaceuticals, Roku

A graphic look at selected stock activity for the week ended on Nov. 10, 2017. Includes J.C. Penney, Valeant Pharmaceuticals, and Roku......»»

Category: marketSource: barronsNov 16th, 2017

It’s Not a Buy? Why Valeant’s Stock Could Have 25% Upside

Yup! Things seem to be looking up for Valeant Pharmaceuticals International (VRX). The drug maker reported third quarter per-share.....»»

Category: blogSource: barronsNov 16th, 2017

Valeant: Is the Rally Over?

Last week, Valeant Pharmaceuticals International (VRX) rallied after the drug maker unveiled an estimate-beating earnings report that re.....»»

Category: blogSource: barronsNov 13th, 2017

Valeant issues $750 million in debt to pay down debt

Valeant Pharmaceuticals International Inc. said Monday it was launching a private offering of $750 mi.....»»

Category: topSource: marketwatchNov 13th, 2017

Valeant Pharma: Why This Bear Still Growls

It’s been a big week for Valeant Pharmaceuticals International (VRX). The troubled drug maker released estimate-beating third quarter.....»»

Category: blogSource: barronsNov 10th, 2017

Called to Account: Valeant is providing the media with an earnings metric that the SEC told it to stop using

Valeant Pharmaceuticals International Inc. has been directed by the Securities and Exchange Commission to clean up its use of nonstandard numbers, but the company is now sending one number to reporters that the regulator has rejected......»»

Category: topSource: marketwatchNov 9th, 2017

Valeant Pharmaceuticals (VRX) in Focus: Stock Moves 5.5% Higher

Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares nearly 6% on the day amid huge volumes. Valeant Pharm.....»»

Category: personnelSource: nytNov 9th, 2017

Here"s What Overshadowed Valeant Pharmaceuticals in October, Pushing Its Shares Down 18%

Is there a light at the end of this tunnel?.....»»

Category: topSource: foxnewsNov 8th, 2017

Valeant Pharmaceuticals Intl (NYSE:VRX) Jumped Over 17%

Valeant Pharmaceuticals Intl (NYSE:VRX) Jumped Over 17% Overall, the bias in prices is: Upwards. Short term: Prices are moving. Intermediate term: Prices are trending. By the way, prices are vulnerable to a correctio.....»»

Category: topSource: livetradingnewsNov 8th, 2017

Valeant Pharmaceuticals International, Inc. 2017 Q3 - Results - Earnings Call Slides

Valeant Pharmaceuticals International, Inc. 2017 Q3 - Results - Earnings Call Slides.....»»

Category: topSource: seekingalphaNov 8th, 2017

Valeant Up 17% After Q3 Report

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are trading higher by $2.06 (17 percent) at $14.10 in Tuesday's session. read more.....»»

Category: blogSource: benzingaNov 7th, 2017